Rhabdomyosarcoma

Clinical Trials

Below is a list of Rhabdomyosarcoma clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Phase 3 Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
The current standard treatment for rhabdomyosarcoma (RMS) is surgery to remove as much tumor as possible, chemotherapy (anti-drug therapy) with vincristine, dactinomycin and cyclophosphamide (together called VAC therapy), and, for almost all tumors, radiation therapy (treatment with high energy X-rays).
Read more

Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
This study is being done to:
- Find out the most effective treatment with the least amount of therapy that will still cure patients with low risk rhabdomyosarcoma

Results of past research studies with low-risk rhabdomyosarcoma patients show that using the three chemotherapy medicines (including cyclophosphamide) helps to cure more patients, but cyclophosphamide at the high doses that were used in these past studies can cause late effects.

The goals of this study are to see if:
1. Lower doses of cyclophosphamide used together with current standard doses of vincristine and dactinomycin can be as effective or better in curing patients as using the standard doses of vincristine and dactinomycin
2. The length of treatment can be shortened
Read more